Compounds of blood or its constituents and process of making same.



Z5. c solved 1n blood are not, of course, capable of top amen pr :1

To all whom. it mm codwern:

Be itf ltnoiin 'that I, Earn) 'Scnnrrms, a citii'e'ii of 'tli eSivissConfederation, and residifigi l it Basel, Switzerland, have invented aceltiii' ncw and useful Improved Gom- Constituents and of which the fol-Process of Making Same, lowiiigfis specification.

Flt silbject-matter of'my invention is a rot-ass ss: manufacturingcompounds of loe d iji constituents thereof and aromatic stilfoliic'acids." Y

I have foundthat by allowing aromatic sulftiiiic ti'eids .e. g? guaiacolsulfonic acid, to act on blood or constituents thereof, I canobtairr/jflpublep compounds insoluble. in waterfroln the constituents ofblood and the sulfonic-acidin question. I may add guaiacol sulfonic-acidas sucli, or I may liberate it from a mixture of blood or constituentsthereof with sulfoguaiacate salts by means of stronger acids, when itusequently acts in stain nascemli.

I may employ blood of various origin and various nature. The inorganicsalts distaking part in this reaction. My process is not lnmted toguanwol-sulfonic acid but, so

.far as has been observed hitherto, may be carried into practice withthe aid' of any aromatic sulfonic-acid.

The new double-compounds are obtained by mixing blood or constituentsthereof until a distinct acid reaction is obtained withthe sulfonic-acidat an ordinary temperature, and thereupon separating the precipitateobtained from the mother-lye,

New and therapeutically. valuable products are obtained according to myinvention. They differ particularly sharply from all combinationsv ofalbumin with therapeutically operative substances heretofore employed.

My process fundamentally differs from those described in'the GermanPatents No. 84,551, Class 12 and No. 112,933, Class 30, because in theseknown processes it is a. matter, on the one hand, of a coagulationprocess in the presence of citric acid, on the. other hand, of theproduction of products -'split from blood by the action of powerfulmineral acids. In contradistinction to these known processes, accordingto my invention 1111 the valuable constituents of blood with thecxception of the inorganic salts are obtained without a coagulationprocess and Application filed May 10, 1911. Serial No. 626,236.

STATES PATENT OFFICE.

.Enrrr.-.s'c1iEIrLIN, or BASEL, SWITZERLAND;

gpmgglgns; zroopfloal:rrs QONSTI'IUENTS AND PROCESS or MAKING SAME.

Patented Jan. 23, 1912.

without destruction in their genuine form as stable double compounds; Itmay be supposed that the aroinatic sulfonic-ac'ids anchor theIlln-lich'sside chains of the albumin molecules and preserve these fromthe changes to which they are always subject in the known process (by a.coagulation process or the action of acids). Further, it is generallywell-known to bind therapeutically operative bodies to albumins, c.ovalbumin, blood albumin, in order to convert these i into a forminsoluble'in gastric juice, so that the therapeutic action becomesoperative only in the alkaline intcstinal juice; compare, for example,the German patent specifications 100,707, 88,029, Class 30 and. 102,050,Class 12", llmrmazc'ut. v(Dznfrallzall? 4-7 (1906), p. 354; underTorosan 'an'd Hagers Ilamlimclz. (701' Phat-1n. lraris, supplementaryvolume (1908), .p'ages 592 and 593 under Pilula Ilaemoglobini cumGuajacolo. In contradistinetiofl to these known processes, according tomy invention Isolve the problem of obtaining the constitutents of theblood with the peculiarities peculiar to them by anchoring thealbumin-like molecules in the blood with aromatic sulfonicacidswhich, assuch, are therapeutically indifferent, whereas in the above-mentionedknown processes the albumin molecule solely serves as a protectiveenvelop for the therapeutically operative substances. Also, a -solutionof sulfoguaiacate of potassium in blood-serum is known andtherapeutically employed. See Hagers I1 mulbuch (Zer Iharm. I Ware-is,supplementary volume @908, page 12 under Tlhiocolscrum. This preparationisa simple mixture and no anchor? ing of the constituents of serum withguaiacol sulfonic acid takes place even under theaction of thehydrochloric acid of the gastric imperfectly indilute alkalis; they areinsoluble in organic solvents and give no characteristic reactions withalbumin reagents,

.chlorid of iron, permanganate of potassium and silver nitrate solution.

- The property of being insoluble in acids I but soluble in alkalis,however, leads to the.

conclusion that the bodies pass the stomach und nnposed in order tobe-assimilated in the alkaline intestinal juice. Thebodiesareunlimitedly durable, can be readily apportioned into doses andenableblood orconstitucnts thereof which have been made specilicall yoperative by inoculation by the production or enricl'unent oi immunesubstances or anti-bodies to be administeredthrough the mouth, whereasthe known tuberculin preparations can only be therapeutically cmploycdin the form of injections. Thus, for example, blood of bovine-vaccinatedanimals, anchored by aron'iatic sultonic-acids, retains itsantituberculin properties unchanged for a long time.

.lfixzuuple: An aqueous solution of guaiacolsullonie-zuzid is allowed toflow into a portion of fresh animal blood, defibrinated or not, at anordinary ten'i 'ierature while agi-. tating the same until the acidreaction to congo no longer disappears. The precipitated PlOtlllCl. isseparated from the motherlyc, washed with water and dried at atemperature below 100" C.

I claim:--

l. The hereimlescribed process of making compounds of blood andits'constituents with aromatic sulfonic-acids, which comprises reactingon blood eonstituents'with an aromatic sulfouicacid.

2. The hereindescribed process of making compounds ofblood and itsconstituents with aromatic sulfonie-acids, which comprises reacting onblood constituents with an aqueous solution of guaiacol sulfonic-acid.

3. The herein described double compounds of a blood constituent and anaromatic sulionic-acid, which are stable, insoluble in water, diluteacids and dissolve slowly in dilute alkalis, and give no characteristicreaction with albumin reagents.

4:. The hereindescribed process, which comprises reacting on bloodconstituents of an inoculated animal with an aromatic sulfonicacid,separating the precipitate and drying the same below the destructivetemperature for-the antitoxin. 1

5. The hereindescl'ibed process, which comprises reacting on bloodconstituents of an inoculated animal with a gnaiacol sulfonicacid,separating the/precipitate and drying the same below the-destructivetemperature for the antitoxin.

In testimony whereof, I aflix my signature in'the presence of twowitnesses.

I EMIL SCHEITLIN.

Witnesses: I

' SAMUEL I-IoLLINonR,

ARNOLD Zmsnn.

